Skip to content
Company Analysis

Emergent BioSolutions Inc. EBS

A comprehensive view of key metrics, scores, and financial health for Emergent BioSolutions Inc.

Overview of Emergent BioSolutions Inc.

EBS NYQ
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
Emergent BioSolutions Inc. (EBS), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $6.44, about 375.0% undervalued vs fair value, -37.3% 1Y return, ranked 740/1145 in sector.
Metrics P/E 13.3× Rev Growth -30.4% ROE 10.5% Gross Margin 53.7%
USD 6.44
-5.43%
(Delayed)
• Vol 90d: 84.3%
52-Week Range
Market Cap
$330.20M
Enterprise Value
$772.30M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 88%
Confidence: 92%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.emergentbiosolutio...
HQ Gaithersburg, MD
Employees 900
Fiscal year Dec 31

Next Events

Earnings Nov 2 Call: Nov 2

Fair Value Snapshot

Bear Base Bull
$28
$31
$33
Current: $6.44 +375% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$705.2M
-30.4%%
Gross Profit
$379.0M
14.1%%
R&D Expense
$53.2M
-24.8%%
Operating Income (EBIT)
$142.1M
297.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
120.1%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
3
Active Leaks
2/3
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Emergent BioSolutions Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
66
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Consistent Cash Generation Cash generation is strong and consistent (score 0.88).
  • Cost Leadership Position Operating margin at 80.0th percentile with strong OpEx control demonstrates cost leadership.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
56
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 95% Coverage
Trade-Off Triangle Visualization A ternary plot showing EBS's balance between Growth (20.2%), Profitability (44.9%), and Safety (35.0%). Growth 20% Safety 35% Profitability 45%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

31th percentile vs peers
31
Key Signals
EPS Growth YoY 1.26 85p Rev Growth YoY -30.4% 16p Revenue CAGR 3Y -13.1% 17p TSR -78.9% 2p
Strengths
  • EPS Growth YoY in top 20% of peers (1.26, 85th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • FCF Margin in top 20% of peers (22.2%, 85th percentile)
  • Current Ratio in top 20% of peers (5.01, 88th percentile)
Risks
  • Rev Growth YoY in bottom 20% of peers (-30.4%)

Profitability

69th percentile vs peers
70
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

54th percentile vs peers
54
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Emergent BioSolutions Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$30.59
- - -
+375.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000